Company / Operating Income
Amneal Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$394.1M
FY2025
5-year range
-$248.7M / $394.1M
FY2021-FY2025
Trend
+58.1%
vs FY2024
Sector context
#20 of 204
Health Care
What the data says
Among 204 Health Care companies, Amneal Pharmaceuticals, Inc. is in the top 10% for operating income. Operating Income has increased for 4 consecutive years, from -$249M in FY2021 to $394M in FY2025.
Based on SEC 10-K filings.
$394M in FY2025. Top quartile in the Health Care sector.
Improved from $153M to $394M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 204This company $394.1M Sector average $107.7M
▼
+265.9% above sector average
Key checks
Key Insights
- Amneal Pharmaceuticals, Inc.'s operating income has grown for 4 consecutive years.
- In FY2025, operating income increased 58.1% year-over-year.
- Ranks #20 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $394.1M | +58.1% |
| FY2024 | $249.3M | +63.3% |
| FY2023 | $152.7M | +260.9% |
| FY2022 | -$94.9M | +61.8% |
| FY2021 | -$248.7M | -1164.1% |
| FY2020 | -$19.7M | -108.0% |
| FY2019 | $245.1M | -14.0% |
| FY2018 | $284.9M | +16.2% |
| FY2017 | $245.1M | -14.0% |
| FY2016 | $284.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026